1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets

Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets

Summary

GBI Research's latest report, "Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets" assesses developments within the key elements of market access such as Health Economics and Outcome Research (HEOR), Health Technology Assessment (HTA) as well as pricing and reimbursements strategies for pharmaceutical products. This new report also discusses the need to integrate market access strategies earlier into the drug development process, in order to save time and costs related to conducting additional studies to prove the added benefits of a product. Additionally, our new study analyses the role of HTAs in market access and alternatives that could be used in cases where there is limited evidence. Detailed analysis of pricing and reimbursement policies in North America, five key European countries and Japan are also included in this report along with a myriad of relevant case studies. In order to gain optimum market access, companies have to analyze the economic benefit of the treatment, the level of competition and the required reimbursement support.

Scope

Payers continue to play an important role in market access. Products are increasingly being rejected for reimbursement, adversely affecting the market share of these products.
- What strategies can pharmaceutical companies implement in order to overcome these challenges?
HEOR plays a critical part in market access
- How does HEOR help internal decision making?
- How can a systemic value development plan (SVDP) optimize HEOR?
- How do cost-effectiveness analyses play a role in the commercial success of a new product?
HTA has gained importance in reimbursement decisions
- What are the different concepts and general processes involved in HTA?
- What are the key benefits of HTA?
Pricing and reimbursement are the key elements of market access
- What are the most important factors considered in pricing decisions?
- What are the pricing and reimbursement policies in the US, Canada, UK, Germany, France, Italy, Spain and Japan?

Reasons to buy

This report will allow you to -
- Gain insights into current market access strategies and evolving approaches: This report describes fundamental concepts about market access, its key elements and the evolving landscape in key markets.
- Understand the role of HEOR in market access and pricing: This report provides insights about role of HEOR in market access and the different economic aspects measured in these studies.
- Understand HTA and its role in reimbursement: This includes detailed analysis on the benefits of HTA in market access, the various dimensions of HTA as well as case studies that highlight the role of these studies in the potential commercial success of a product.
- Review the involvement of Risk Sharing Agreements (RSAs) in market access: Includes details about the involvement of a RSA when there is limited evidence available for conducting HTAs as well as the various approaches involved in RSAs
- Understand pricing of pharmaceutical products in the US: Includes pricing policies in the US along with the impact of the Affordable Care Act (ACA) on pricing decisions. Specific case studies deliver analyses of the current market access landscape in the US.
- Assess pricing and reimbursement in Europe and Japan: Includes pricing and reimbursement policies in five key European countries and Japan. Specific case studies demonstrate critical market access factors to be considered in these countries.

Table Of Contents

Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets
Executive Summary
Introduction
Health Economic and Outcomes Research (HEOR)
A Systemic Value Development Plan for HEOR
Types of Economic Evaluations
Overview of Cost-Effectiveness Analysis
Quality-Adjusted Life Year in HEOR
Pharmacoeconomic Modelling Methods
Health Technology Assessment (HTA) in Market Access
Key Benefits of HTA
Process and Dimensions of HTA
Principle HTA Regulatory Agencies
Case Studies
Risk Sharing Agreements When Limited Evidence is Available for HTA
Pricing and Reimbursement
Factors Affecting Pricing Decision
Pricing of a New Drug
Pharmaceutical Pricing Policies in the US
Impact Of Affordable Care Act on Market Access
Case Studies
Pharmaceutical Pricing and Reimbursement Policies in Canada
Pharmaceutical Pricing and Reimbursement Policies in Europe (UK, Germany, France, Italy and Spain)
Case Studies
Parallel Trade in Europe
Pharmaceutical Pricing and Reimbursement Policies in Japan
Economic Analysis Alongside Clinical Trials
Harmonization of Drug Approval and Marketing for Effective Market Access
Key Challenges for Achieving Optimum Market Access
Key Takeaways

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.